Audit of Indian Clinical trials on COVID-19
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/03/031687
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 1071
Inclusion Criteria
all studies registered under CTRI for COVID-19 infections in the year 2020 and 2021
Exclusion Criteria
Studies not related to COVID-19
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Total number of trials/studies registered for COVID-19 <br/ ><br>2.Phase, (Phase I–IV) <br/ ><br>3.Nature (interventional or observational) <br/ ><br>4.Source of funding (Pharmaceutical Industry/Government of India/Institute Funded) <br/ ><br>5.Status of DCGI approval <br/ ><br>6.Status of Ethics committee approval <br/ ><br>7.National/International <br/ ><br>8.Health type <br/ ><br>9.Severity of the condition <br/ ><br>10.Randomization type <br/ ><br>11.Blinding <br/ ><br>12.Primary and secondary end points <br/ ><br>13.Sample size <br/ ><br>14.Duration <br/ ><br>Timepoint: At the end of the study
- Secondary Outcome Measures
Name Time Method Total number of trials/studies registered for COVID-19 <br/ ><br>2.Phase, (Phase I–IV) <br/ ><br>3.Nature (interventional or observational) <br/ ><br>4.Source of funding (Pharmaceutical Industry/Government of India/Institute Funded) <br/ ><br>5.Status of DCGI approval <br/ ><br>6.Status of Ethics committee approval <br/ ><br>7.National/International <br/ ><br>8.Health type <br/ ><br>9.Severity of the condition <br/ ><br>10.Randomization type <br/ ><br>11.Blinding <br/ ><br>12.Primary and secondary end points <br/ ><br>13.Sample size <br/ ><br>14.Duration <br/ ><br>Timepoint: At the end of the study
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of SARS-CoV-2 were prioritized in CTRI/2021/03/031687 observational studies?
How do antiviral therapies in CTRI/2021/03/031687 compare to standard-of-care for hospitalized patients?
Which biomarkers were identified in CTRI/2021/03/031687 to predict clinical outcomes in severe COVID-19?
What adverse events were reported in CTRI/2021/03/031687 observational studies of experimental treatments?
What combination therapies were assessed in CTRI/2021/03/031687 for enhancing SARS-CoV-2 treatment efficacy?